Summary & Overview
CPT 4196F: Ongoing DMARD Therapy for Established Rheumatoid Arthritis
CPT code 4196F documents that a clinician has prescribed a disease modifying antirheumatic drug (DMARD) for a patient with rheumatoid arthritis who is already on such therapy rather than starting it for the first time. This distinction—ongoing DMARD management versus initiation—affects clinical documentation and payor adjudication, and is widely used across outpatient rheumatology settings nationally. Key payers typically referenced in coverage and claims guidance include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise briefing on the clinical context for DMARD use in rheumatoid arthritis, the service setting for ongoing therapy management, and the implications for coding and claims submission. The publication summarizes benchmarking and payer coverage themes where available, highlights relevant policy or documentation considerations, and provides clinical context to help payers and providers align on how this code is used in routine rheumatology care. Data not available in the input is indicated where applicable; the focus remains on national applicability rather than state-specific rules.
Billing Code Overview
CPT code 4196F indicates that a provider prescribes a disease modifying antirheumatic drug (DMARD) therapy for a patient with rheumatoid arthritis who is not receiving this therapy for the first time. The code documents ongoing DMARD management rather than initiation.
Service Type: Outpatient prescription management and ongoing pharmacologic disease-modifying therapy for rheumatoid arthritis.
Typical Site of Service: Ambulatory care settings such as rheumatology clinics, physician offices, and outpatient infusion or injection centers where ongoing DMARD therapy is managed.
Clinical & Coding Specifications
Clinical Context
A 62-year-old female with a 10-year history of seropositive rheumatoid arthritis presents to her rheumatology clinic for routine follow-up. She has been treated previously with methotrexate and subsequently transitioned to a biologic DMARD after inadequate response. At this visit the provider documents continued need for ongoing disease-modifying antirheumatic drug therapy and prescribes a refill of her current biologic agent. The clinical workflow includes medication reconciliation, assessment of disease activity (joint exam, patient-reported outcomes), review of laboratory monitoring (CBC, LFTs, TB screening as appropriate), discussion of adherence and adverse effects, and issuance of a prescription or electronic authorization for continuation of the DMARD. The encounter does not represent initiation of DMARD therapy; it documents continuation or re-prescription of an established DMARD regimen for rheumatoid arthritis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service | Use when the E/M visit for medication management is separate from a minor procedure or test performed the same day |
59 |